



# NAoMe

National Audit of  
Metastatic Breast Cancer

NAoMe, Clinical Effectiveness Unit

Royal College of Surgeons of England  
38-43 Lincoln's Inn Fields  
London WC2A 3PE

E: [BreastCancerAudits@rcseng.ac.uk](mailto:BreastCancerAudits@rcseng.ac.uk)

T: 020 7869 6610

[NAoMe\\_news](#)


## NAoMe Newsletter, October 2024

### Highlights

- 1** Quality Improvement Plan
- 2** State of the Nation Report
- 3** Upcoming Publications
- 4** Quarterly Clinical Performance Indicator Report

### Quality Improvement Plan

Our Quality Improvement Plan defines 10 key performance indicators for the NAOme.



These are mapped to five overarching quality improvement goals based on national guidelines and standards for metastatic breast cancer care.

These performance indicators will be used to monitor progress towards quality improvement goals and to stimulate improvements in metastatic breast cancer care in England and Wales.



The NAOme Quality Improvement (QI) Plan is now published and can be accessed [HERE](#).



### State of the Nation Report

The first NAOme State of the Nation (SotN) report and supplementary materials are now available [HERE](#).

This includes:

- National data for key performance indicators for metastatic breast cancer care.
- A data viewer with break down of individual results for each NHS breast unit.
- Recommendations and a local action plan for quality improvement in your organisation based on the above.



### Upcoming Publications

**Next Quarterly Reports:**  
January 2025  
April 2025

**State of the Nation Report:**  
September 2025 (TBC)

### CONTACT US

E-mail any breast audit-specific questions to:  
[breastcanceraudits@rcseng.ac.uk](mailto:breastcanceraudits@rcseng.ac.uk)

Follow us on X (formerly Twitter):  
[@NAoMe\\_news](#)

### First Quarterly Clinical Performance Indicator Report



The first expanded NAOme Quarterly Clinical Performance Indicator Report was published on 10th October 2024.

Access results for your NHS organisation including:

- Data completeness on key data items for people with "de-novo" metastatic breast cancer.
- Patient characteristics for people with "de-novo" and "recurrent" metastatic breast cancer.
- Two performance indicators for patients with "de-novo" metastatic breast cancer: i) Multidisciplinary Team discussion, ii) Death within 30 days of a chemotherapy cycle.

You can access the Quarterly Report [HERE](#).



This email was sent to you by NAOme, part of the National Cancer Audit Collaborating Centre (NATCAN) based at the Royal College of Surgeons of England. To ensure continued receipt of our emails please add us to your address book or safe list. In accordance with the General Data Protection Regulation (GDPR), NATCAN is committed to protecting your privacy. If you wish to know more please access our [privacy policy](#). If you wish to unsubscribe from all NAOme communications, please click [here](#). © RCSEng 2024, Registered Charity No. 212808